GSK Buys Tesaro For $5 Billion In Dramatic Bet On Cancer Genetics

19

GlaxoSmithKline announced this morning that it will buy Tesaro, the maker of the ovarian cancer drug Zejula, for $5.1 billion in cash in a dramatic bet that the London-based drug giant can see opportunities connected to the genetics of cancer drugs better than the stock market.

More: https://www.forbes.com/sites/matthewherper/2018/12/03/gsk-buys-tesaro-for-5-billion-in-dramatic-bet-on-cancer-genetics